NCT03810066View on ClinicalTrials.gov

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

September 30, 2022

Conditions
NSCLCEGFR T790MFDG-PET
Interventions
DRUG

Osimertinib

All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).

Trial Locations (1)

45147

Prof. Dr. med. Martin Schuler, Essen

All Listed Sponsors
lead

University Hospital, Essen

OTHER

NCT03810066 - Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) | Biotech Hunter | Biotech Hunter